Anxiety-Related Adverse Event Clusters ID'd After Janssen Vaccine
MONDAY, May 3, 2021 -- Syncope and other anxiety-related events occur more often after receipt of Janssen COVID-19 vaccines than influenza vaccination, according to research published in the April 30 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Noting that on April 7, 2021, after five weeks of use of the Janssen COVID-19 vaccine, reports were received of clusters of anxiety-related events after vaccine administration from five vaccination sites, Anne M. Hause, Ph.D., from the CDC COVID-19 Response Team, and colleagues further investigated these cases. Site staff members were interviewed to gather additional information. While an investigation took place, four of the five vaccination sites temporarily closed.
The researchers found that among 8,624 Janssen COVID-19 vaccine recipients, there were 64 anxiety-related events overall, including 17 reports of syncope for vaccines administered during April 7 to 9, 2021. The prevalence of anxiety-related adverse events varied from 5.2 to 13.5 per 1,000 persons vaccinated at the five sites. On review of all reports, the Vaccine Adverse Event Reporting System reporting rate of syncope after the Janssen COVID-19 vaccination was 8.2 per 100,000 doses during March and April 2021. Reports of syncopal events were compared to those reported after influenza vaccine administration in the 2019 to 2020 influenza season; the reporting rate of syncope was 0.05 episodes per 100,000 doses of influenza vaccine.
"Increased awareness of anxiety-related events after vaccination will enable vaccination providers to make an informed decision about continuing vaccination," the authors write.
© 2021 HealthDay. All rights reserved.
Posted: May 2021
Further Support and Information on COVID-19
Read this next
THURSDAY, May 6, 2021 -- The BNT162b2 mRNA COVID-19 vaccine has lower efficacy among patients with chronic lymphocytic leukemia (CLL) and induces lower neutralizing antibody...
THURSDAY, May 6, 2021 -- Self-reported human papillomavirus (HPV) vaccination rates for young adults, whether for receipt of a dose at any age or between ages 18 and 21 years, are...
WEDNESDAY, May 5, 2021 -- The Pfizer COVID-19 vaccine has been approved by Canadian health officials for use in children ages 12 to 15 years. It was already authorized for anyone...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.